Clinical Trials
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
Imetelstat With Paclitaxel in Patients With Breast Cancer
A Randomized Phase 2 Study of Imetelstat (GRN163L) in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Helpful Information
- Progression-free survival (PFS) is the length of time during and after treatment in which a patient is living with a disease (or cancer) that does not get worse.
- Objective response rate measures how many patients in the study have had either a partial or complete response to treatment.
- Clinical benefit rate is a measurement of the proportion of patients whose cancer has not become worse after six months.
- Standard of care is a treatment that experts agree is appropriate, accepted, and widely used. It is also often called best practice, standard medical care, or standard therapy.
Geron is enrolling patients in a clinical trial to determine the potential benefit of our product candidate, imetelstat, as a therapy for patients diagnosed with locally recurrent or metastatic breast cancer. This study is open to patients who have not received chemotherapy or who have received one non-taxane based chemotherapy for metastatic breast cancer.
In this Phase 2 clinical trial, our clinical researchers and investigators are studying how imetelstat, when given in combination with paclitaxel, may impact the progression-free survival rates of women currently living with breast cancer (with or without bevacizumab).
Additionally, we are collecting data on the objective response rate and clinical benefit rate of imetelstat when combined with paclitaxel (with or without bevacizumab).
Upon acceptance into the study, patients will be assigned by chance, or "randomized", to separate groups that compare results of treatment with imetelstat in addition to a standard of care against standard of care alone.
In this study, the standard of care is paclitaxel (with or without bevacizumab).
Imetelstat is an investigational treatment for cancer in development by Geron and has not been approved by the FDA or any other regulatory agency.
About Imetelstat
Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely. One of Geron's potential anti-cancer strategies is to stop or slow down the growth and spreading of tumors by inhibiting telomerase activity. Learn more
Cancer Definitions
To learn more about the terms and definitions used in cancer clinical studies you may find the National Cancer Institute Dictionary of Cancer Terms a useful resource.
Para obtener más información acerca de los términos y las definiciones utilizadas en los estudios clínicos sobre el cáncer es posible que el Instituto Nacional del Cáncer Diccionario de cáncer en un recurso útil.
How to Participate
To learn more about how to participate in this clinical trial, please visit ClinicalTrials.gov for the full trial summary and enrollment criteria.
Additionally, patients or their physicians may directly contact the nearest trial center for more information about how to participate. The study is currently being conducted in multiple trial centers across the United States and Canada.
Novel Approach
Imetelstat inhibits the activity of the enzyme telomerase, a key target for anti-cancer therapeutics.
Learn more
